Zinc octa-n-alkyl phthalocyanines in photodynamic therapy: photophysical properties, accumulation and apoptosis in cell cultures, studies in erythrocytes and topical application to Balb/c mice skin

Kaestner, Lars, Cesson, Maro, Kassab, Kawser, Christensen, Terje, Edminson, Paul D., Cook, Michael J., Chambrier, Isabelle and Jori, Giulio (2003) Zinc octa-n-alkyl phthalocyanines in photodynamic therapy: photophysical properties, accumulation and apoptosis in cell cultures, studies in erythrocytes and topical application to Balb/c mice skin. Photochemical & Photobiological Sciences, 2 (6). pp. 660-667. ISSN 1474-905X

Full text not available from this repository.

Abstract

Two octa-substituted phthalocyanines, namely 1,4,8,11,15,18,22,25-octakis(decyl) phthalocyaninato zinc(II) (ZnODPc) and 1,4,8,11,15,18,22,25-octakis(pentyl) phthalocyaninato zinc(II) (ZnOPPc), were investigated for their use in photodynamic therapy ( PDT) after topical application. Both substances exhibited favourable properties as photosensitisers in vitro: absorption maxima around 700 nm with absorption coefficients of about 190000 (M-1 cm(-1)), a singlet oxygen quantum yield of 0.47 +/- 0.02 (ZnODPc), and good accumulation in keratinocytes and. broblasts. Cell death after phthalocyanine-photosensitisation appeared to occur mainly via apoptosis. The in vivo experiments demonstrated a good accumulation of the phthalocyanines after topical application in a tetrahydrofuran - azone formulation onto the dorsal skin of Balb/c mice: [(4.6 - 4.7) +/- 1.0]% of deposited dye could be recovered after 3 h from deposition. ZnODPc showed significantly better skin-photosensitising properties than ZnOPPc and is therefore a potential candidate for the treatment of psoriasis.

Item Type: Article
Faculty \ School: Faculty of Science > School of Chemistry (former - to 2024)
Depositing User: Rachel Smith
Date Deposited: 10 May 2011 14:16
Last Modified: 24 Sep 2024 10:11
URI: https://ueaeprints.uea.ac.uk/id/eprint/30132
DOI: 10.1039/b211348a

Actions (login required)

View Item View Item